New study shows children benefited most from gene therapy for LCA, a rare eye disease

"While other studies have shown similar results, an important finding from this study is that the young patients saw the greatest benefit in treatment. In addition, this study for the first time demonstrates improvement in visual field by using visual field modeling and assessment," said Timothy Stout, M. D., Ph.D., M.B.A., a senior author and study surgeon who previously worked at OHSU Casey Eye Institute and is now director of the Baylor Cullen Eye Institute.

The study included 8 adults and 4 children ages 6 to 39, and showed that treatment for LCA and SECORD delivered by subretinal injection in the poorer-seeing eye, was safe, the primary outcome for Phase I clinical trials. Nine out of 12 patients experienced an improvement in visual acuity (sharpness of vision) or an improvement in visual field.

In order to more accurately measure visual field, the total area in which objects can be seen (both central and side vision), Richard Weleber, M.D. of OHSU's Casey Eye Institute, senior author and professor of ophthalmology in the OHSU School of Medicine, Casey Eye Institute developed a novel quantitative visual field analytic tool, called Visual Field Modeling and Assessment.

"I am very optimistic about these study findings," said Weleber. "Gene replacement therapy has proven to be the most promising method to halt progression of childhood blindness due to single gene defects. The eye is a perfect platform for gene therapy because we can treat one eye to see how it responds compared to the other eye."

Gene therapy is a new approach to treating rare genetic diseases and has shown a lot of promise in treating rare genetic eye diseases such as LCA due to mutations of the RPE65 gene. For this study, surgeons used a viral vector to insert a normal copy of the mutated gene (RPE65) into the retinal cells of the patient's eye to restore retinal function.

OHSU Casey Eye Institute's gene therapy program is world-renowned, with leading experts currently overseeing five gene therapy trials, the most retinal gene therapy clinical trials being conducted at a single institution. Patients travel from all over the world to participate in these groundbreaking studies targeting severe inherited blinding disorders.

"Treatments for childhood blindness have profound effects because these children have their whole lives ahead of them," said David Wilson, M.D., director of the OHSU Casey Eye Institute, chair of the Department of Ophthalmology in the OHSU School of Medicine and study co-author. "Demonstrating the effectiveness of gene therapy in the eye will have broad implications for the rest of medicine as well."

The study was sponsored by Applied Genetic Technologies Corporation (AGTC), and supported by the U.S. Food and Drug Administration's Office of Orphan Products Development (grant no. R01 FD003694), the National Eye Institute at the National Institutes of Health (grant no. U10EY013729) and the Foundation Fighting Blindness.

Other authors for the article, titled, "Results at 2 Years after Gene Therapy for RPE65-deficient Leber Congenital Amaurosis and Severe Early-Childhood Onset Retinal Dystrophy," include: Mark E. Pennesi, Laura R. Erker, Lauren Jensen and Maureen T. McBride of OHSU Casey Eye Institute; Shalesh Kaushal, Terence R. Flotte and Margaret Humphries at University of Massachusetts Medical Center; Roberto Calcedo at University of Pennsylvania; William W. Hauswirth at University of Florida School of Medicine; and Jeffrey D. Chulay of AGTC.